Abcam, ab306523, APC Anti-Tcl1 antibody [SP248]

Size: 100µL
Rabbit Recombinant Monoclonal Tcl1 antibody - conjugated to APC.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:SP248,
Isotype:IgG,
Conjugation:APC,
Excitation/Emission:Ex: 650nm, Em: 660nm,
Carrier free:No,
Applications:Antibody Labelling, Target Binding AffinitySee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
conjugated primary antibody
is "made to order" and it is released using a quantitative quality control method that ensures binding affinity and labelling efficiency of the conjugate. Via leveraging the power of the
Lightning-Link® conjugation technology
, Abcam will deliver highly consistent recombinant conjugates in <2 weeks, giving you access to an ever growing portfolio of antibody-label combinations.
For suitable applications and species reactivity, please refer to the unconjugated version of this clone.
How are conjugated primary antibodies validated?
This conjugated primary antibody is released using a quantitative quality control method that evaluates binding affinity post-conjugation and efficiency of antibody labeling.
For suitable applications and species reactivity, please refer to the unconjugated version of this clone.
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.4Preservative: 0.02% Sodium azideConstituents: PBS, 1% BSA, Shipped at conditions-Blue Ice, Appropriate short-term storage duration-1-2 weeks, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Aliquoting information-Upon delivery aliquot, Storage information-Avoid freeze / thaw cycle, Store in the dark

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
The TCL1 (T-cell leukemia/lymphoma protein 1) also known as TCL1A is an important protein involved in cellular processes. TCL1 has a molecular mass of approximately 14 kDa and plays roles in signal transduction pathways. The protein is expressed in various tissues including the thymus lymph nodes and spleen. TCL1 is particularly important in T-cell development and function. It functions at a mechanistic level by interacting with other proteins thereby influencing cell signaling pathways essential for lymphocyte proliferation and survival.
Biological function summary
TCL1 enhances the activity of the AKT kinase an important component of cellular signaling that modulates cell growth and survival. This protein does not form any large complex but acts through AKT phosphorylation. The activation of TCL1 leads to the promotion of cell proliferation and prevention of apoptosis especially in lymphocytes. The regulation of these cellular activities by TCL1 suggests its important role in the development of the immune system.
Pathways
The AKT signaling pathway is significantly influenced by TCL1 controlling cell growth division and apoptosis. The interaction of TCL1 with AKT activates the PI3K/AKT pathway an important signal transduction pathway promoting survival and growth in response to extracellular signals. TCL1 indirectly affects the mTOR signaling pathway through its modulation of AKT affecting protein synthesis and cell metabolism. Both pathways emphasize the broad role of TCL1 in maintaining normal cellular functions and growth regulation.
The overexpression or mutation of TCL1 can lead to malignancies such as T-cell leukemia and B-cell lymphoma. In these cancers abnormal TCL1 activity results in enhanced cell survival and proliferation contributing to tumorigenesis. In leukemia TCL1 directly interacts with AKT and its dysregulation becomes pathogenic. Research continues to investigate the involvement of TCL1 in oncogenesis and how its association with AKT and other signaling molecules like mTOR contributes to cancer progression. Understanding these interactions could potentially offer new therapeutic targets for treating related malignancies.